Back to results
CompletedPhase 3

Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design

NCT00798161

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

1218.46.11005 Boehringer Ingelheim Investigational Site

Calgary, Alberta, Canada

+137 additional locations

View on ClinicalTrials.gov
Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design — TrialFind